Mantle cell lymphoma (MCL) represents a relatively uncommon, heterogeneous lymphoma associated with limited overall survival. Targeting of the B-cell receptor pathway in relapsed disease with covalent ...

Mantle cell lymphoma treatment offers options if patients relapse after CAR T-cell therapy, from bispecific antibodies, antibody drug conjugates, and other emerging therapies.

An expert discusses the evolving management of relapsed/refractory (R/R) large B-cell lymphoma (LBCL), illustrating how CAR T ...

Mantle cell lymphoma (MCL) remains one of the more challenging B-cell non-Hodgkin lymphomas, distinguished by its aggressive clinical course and complex molecular signature. Recent investigations ...

Diffuse large B-cell lymphoma is the most common type of lymphoma. It makes up approximately 25% of all non-Hodgkin’s lymphomas, which are cancers that lack defining cells called Hodgkin cells ...

Calquence, an inhibitor of Bruton tyrosine kinase, is also indicated for the treatment of adults with chronic lymphocytic leukemia or small lymphocytic lymphoma. It is supplied as 100mg tablets.

Recent research has suggested auto-HSCT may not improve survival. “The typical patient with mantle cell lymphoma is in their mid- to late 60s, often with medical comorbidities,” Fenske said.

Eli Lilly said on Tuesday its drug for a type of blood cancer was more effective in a head-to-head study against AbbVie's Imbruvica when tested in both untreated and previously treated patients. The ...

Research into mantle cell lymphoma (MCL) aims to find new therapies for this type of blood cancer. MCL is an aggressive type of B-cell non-Hodgkin lymphoma that can present very differently from ...